There is research on this stock available only to PRO subscribers.
Mon, Aug. 25, 4:33 PM
Mon, Aug. 11, 5:03 PM
Mon, Aug. 11, 4:24 PM
Mon, Jul. 28, 8:04 AM
Tue, May. 13, 5:10 PM
Thu, Feb. 13, 10:35 AM
- Biodel (BIOD +5.9%) pushes higher on news it plans to rapidly advance its insulin formulation BIOD-531 to a Phase 2 study in diabetic patients, after seeing positive Phase 1 clinical trial results.
- The company says BIOD-531 was associated with an increased rate of absorption as measured by multiple pharmacokinetic parameters, which support the potential to provide basal insulin needs.
Thu, Feb. 13, 9:13 AM| 1 Comment
Sat, Feb. 8, 8:25 AM
- 24/7's Lee Jackson pinpoints eight small-cap biotech ideas, whose stocks all trade near $5 but with big upside potential; each company has promising clinical trials and in some cases FDA-approved products already on the market or soon to arrive.
- Galena Biopharma (GALE) "may be the home run that biotech investors are looking for," and the stock may be an acquisition target; Novavax (NVAX) has six vaccine candidates undergoing clinical trials and a seventh being readied for a Phase I study later this year.
- Jackson's other favorite biotech opportunities: ARRY, BIOD, PLX, RIGL, SNTA, ZGNX.
- J.P. Morgan has three different ideas for aggressive risk-tolerant investors: ITMN, NPSP and PLX.
Dec. 18, 2013, 4:50 PM
Dec. 17, 2013, 9:11 AM
Dec. 17, 2013, 8:30 AM
- Biodel (BIOD) jumps 14% in premarket trading.
- The company has inked a long-term supply deal with Becton, Dickinson (BDX) for exclusive rights to the BD Uniject SCF Disposable Auto-Disable Injection System.
- BIOD will leverage the device to serve the "glucagon rescue treatment market by replacing antiquated, difficult, and cumbersome multi-part kits with simple, convenient, portable therapies."
- In other words, the company is using the devices to deliver liquid glucagon for the treatment of hypoglycemia. (PR)
Sep. 11, 2013, 12:45 PM
Sep. 9, 2013, 2:49 PM
- Biodel (BIOD -26%) reverses big pre-market gains to trade lower after preliminary results from a mid-stage study of its investigational ultra-rapid-acting mealtime insulin, BIOD-123, in patients with type 1 diabetes were largly positive.
- The only adverse effects recorded were an increased frequency of injection site pain, which appeared to be clinically minor, was short-lived and didn't result in patient dropouts, according to the company.
- The stock has had a big run since April, doubling in value in anticipation of strong Phase II results for the drug.
Sep. 9, 2013, 12:46 PM
Sep. 9, 2013, 9:15 AM
Aug. 12, 2013, 5:16 PM
BIOD vs. ETF Alternatives
Other News & PR